Drug Trial Radar · NCT04595942
Midodrine and Fludrocortisone for Vasovagal Syncope
Last checked: Nov 20, 2026Latest source record: Apr 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,375
Planned (sponsor's estimate)
Start
Nov 19, 2020
Primary completion
Oct 2023
Study completion Dec 2023
Sponsor
- Lead sponsor
- Tehran Heart CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Mahidol University; Rajaie Cardiovascular Medical and Research Center; Tehran Arrhythmia Center; Imam Khomeini Hospital; AJA University of Medical Sciences; Urmia University of Medical Sciences; Isfahan University of Medical Sciences; Shahid Beheshti University of Medical Sciences; Ahvaz Jundishapur University of Medical Sciences
- First posted
- Oct 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Syncope is a common condition which can disturb daily functions of the patients and impair their quality of lives. It contributes to 0.8 to 2.4% of the visits of emergency rooms. Noticeably, studies demonstrated that the lifetime prevalence of syncope is as high as 41% with a 13.5% recurrence rate. The cornerstone of the treatment of vasovagal syncope (VVS), the most common type of syncope, is lifestyle modifications and patient education to avoid potential triggers of syncope. These recommendations alleviate vasovagal spells in many patients; however, some patients experience life-disturbing vasovagal attacks despite compliance with these modifications. This fact underscores the importance of efficient pharmacological interventions as well. Currently, there is an ongoing controversy about the efficacy of midodrine and fludrocortisone as adjunct pharmacological interventions for the prevention of VVS. In the COMFORTS trial, we are going to evaluate the efficacy of midodrine, fludrocortisone, and lifestyle modifications for prevention of vasovagal attacks in patients with VVS.
Conditions
- Syncope, Vasovagal
Interventions
Midodrine Hydrochloride TabletsDrug
Patients will be started on 5 mg Midodrine three times a day and after one week the dosage will be up-titrated to 10 mg three times a day and continued for 12 months. They will receive the medication at four-hour intervals upon rising in the morning (the last dose should not be taken later than 6 PM). In case of intolerance, the dosage will be reduced to 2.5 mg three times a day. Patients will also receive recommendations for lifestyle modifications including drinking 2 to 3 liters of fluid per day, daily consumption of 10 grams of salt, and practicing counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting).
Fludrocortisone Acetate TabletsDrug
Patients will be started on 0.05 mg of fludrocortisone twice daily and after one week the dosage will be up-titrated to 0.1 mg fludrocortisone twice daily taken for 12 months. Patients will also receive recommendations for lifestyle modifications including drinking 2 to 3 liters of fluid per day, daily consumption of 10 grams of salt, and practicing counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting). In this arm, potassium levels will be checked 7-14 days after dose stabilization.
Lifestyle modificationBehavioral
Patients will be recommended to drink 2 to 3 liters of fluid per day, consume 10 grams of salt per day, and practice counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting) for 12 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first episode of syncopeTime frame: The follow-up continues for 12 months after randomization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tehran Heart Center
Tehran, Iran · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.